Moexipril

Information about Moexipril

Moexipril is an angiotensin-converting enzyme (ACE) inhibitor which is used in the therapy of hypertension. Moexipril is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.

Error creating thumbnail:

Moexipril

Mechanism of action of Moexipril

Moexipril (moe ex' i pril) is an ACE inhibitor which is approved for use alone and in combination with other agents in the therapy of hypertension. Like other ACE inhibitors, moexipril inhibits the conversion of angiotensin I, a relatively inactive molecule, to angiotensin II which is the major mediator of vasoconstriction and volume expansion induced by the renin-angiotensin system. Other host enzymes besides that which converts angiotensin I to II may be inhibited as well, which may account for some of the side effects of the ACE inhibitors.

FDA approval information for Moexipril

Moexipril was approved for use in the United States in 1991 and is available in 7.5 and 15 mg tablets in several generic forms and under the trade name Univasc.

Dosage and administration for Moexipril

The typical daily dose in adults is 7.5 to 30 mg in one or two divided doses which is administered long term. Moexipril is also available in fixed dose combinations with hydrochlorothiazide (Uniretic and generics).

Side effects of Moexipril

Common side effects include dizziness, fatigue, headache, cough, gastrointestinal upset and skin rash. Common ACE inhibitors include the following:

• Benazepril
• Captopril
• Enalapril
• Fosinopril
• Lisinopril
• Moexipril
• Perindopril
• Quinapril
• Ramipril
• Trandolapril

• Dailymed label info on Moexipril
• FDA Moexipril

Moexipril Resources
Latest articles Most recent articles Ongoing trials	Wikipedia